Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

Status unconfirmed · Phase 2

Conditions studied: Acute Promyelocytic Leukemia

In brief

The purpose of this study is to determine whether NRX 195183 is effective in the treatment of relapsed or refractory Acute Promyelocytic Leukemia

Key facts

Study ID
NCT00675870
Run by
NuRx Pharmaceuticals, Inc.
People needed
65
Starts
2008-04-01
Last updated by the study team
2008-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.